These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 16374734)

  • 1. Abiraterone. Cougar Biotechnology.
    Madan RA; Arlen PM
    IDrugs; 2006 Jan; 9(1):49-55. PubMed ID: 16374734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of p450 17 as a new strategy for the treatment of prostate cancer.
    Leroux F
    Curr Med Chem; 2005; 12(14):1623-9. PubMed ID: 16022662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel concepts in androgen receptor blockade.
    Hsieh AC; Ryan CJ
    Cancer J; 2008; 14(1):11-4. PubMed ID: 18303477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis, biological evaluation, and molecular modeling of abiraterone analogues: novel CYP17 inhibitors for the treatment of prostate cancer.
    Pinto-Bazurco Mendieta MA; Negri M; Jagusch C; Müller-Vieira U; Lauterbach T; Hartmann RW
    J Med Chem; 2008 Aug; 51(16):5009-18. PubMed ID: 18672868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abiraterone for the treatment of metastatic castrate-resistant prostate cancer.
    Beckett RD; Rodeffer KM; Snodgrass R
    Ann Pharmacother; 2012; 46(7-8):1016-24. PubMed ID: 22714819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abiraterone: current and future use in prostate cancer.
    Ryan CJ
    Clin Adv Hematol Oncol; 2012 Mar; 10(3):180-1. PubMed ID: 22402426
    [No Abstract]   [Full Text] [Related]  

  • 7. Abiraterone and MVD3100 take androgen deprivation to a new level.
    Schmidt C
    J Natl Cancer Inst; 2011 Feb; 103(3):175-6. PubMed ID: 21242338
    [No Abstract]   [Full Text] [Related]  

  • 8. Abiraterone acetate for castration resistant prostate cancer.
    Shah S; Ryan C
    Expert Opin Investig Drugs; 2010 Apr; 19(4):563-70. PubMed ID: 20225998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abiraterone acetate: a promising drug for the treatment of castration-resistant prostate cancer.
    Agarwal N; Hutson TE; Vogelzang NJ; Sonpavde G
    Future Oncol; 2010 May; 6(5):665-79. PubMed ID: 20465382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of abiraterone for prostate cancer.
    Mohler JL; Pantuck AJ
    J Urol; 2011 Mar; 185(3):783-6. PubMed ID: 21239011
    [No Abstract]   [Full Text] [Related]  

  • 11. [Inhibitors of the key enzymes of androgen synthesis: potential agents as targets for prostate cancer].
    Takeda M; Hosaka M
    Nihon Rinsho; 2000 Jul; 58 Suppl():312-6. PubMed ID: 11022738
    [No Abstract]   [Full Text] [Related]  

  • 12. Abiraterone and castration-resistant prostate cancer.
    Burki TK
    Lancet Oncol; 2013 Feb; 14(2):e48. PubMed ID: 23487849
    [No Abstract]   [Full Text] [Related]  

  • 13. Abiraterone in prostate cancer.
    Ryan C
    Clin Adv Hematol Oncol; 2010 Nov; 8(11):761-2. PubMed ID: 21326154
    [No Abstract]   [Full Text] [Related]  

  • 14. Novel secondary hormonal therapy in advanced prostate cancer: an update.
    Van Allen EM; Ryan CJ
    Curr Opin Urol; 2009 May; 19(3):315-21. PubMed ID: 19342958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer expert doubts claims about prostate cancer trial.
    Cole A
    BMJ; 2008 Jul; 337():a979. PubMed ID: 18653636
    [No Abstract]   [Full Text] [Related]  

  • 16. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers.
    Xu Y; Dalrymple SL; Becker RE; Denmeade SR; Isaacs JT
    Clin Cancer Res; 2006 Jul; 12(13):4072-9. PubMed ID: 16818707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abiraterone acetate.
    Logothetis CJ; Efstathiou E; Manuguid F; Kirkpatrick P
    Nat Rev Drug Discov; 2011 Aug; 10(8):573-4. PubMed ID: 21804589
    [No Abstract]   [Full Text] [Related]  

  • 18. Abiraterone. After prostate cancer treatment failure: 4-month survival advantage.
    Prescrire Int; 2012 Jun; 21(128):147-9. PubMed ID: 22822591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer.
    Attard G; Belldegrun AS; de Bono JS
    BJU Int; 2005 Dec; 96(9):1241-6. PubMed ID: 16287438
    [No Abstract]   [Full Text] [Related]  

  • 20. [Advances in the study of steroidal inhibitors of cytochrome P45017alpha].
    Du JJ; Chen HL; Li YC
    Yao Xue Xue Bao; 2013 Jan; 48(1):25-31. PubMed ID: 23600137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.